CEO SUMMARY: AmeriPath’s efforts to become a public company make it the most visible management experiment in the pathology world today. Already considered controversial by many pathologists, should AmeriPath successfully pull off its proposed initial public stock offering, it will assume a leadership position in the industry which cannot be ignored.
PATHOLOGY MAY SOON have its
Subscriber-Only Content. Please Log In.
You are trying to access subscribers-only content. If you are a subscriber, please log in.
If you are not a subscriber, click here to see subscription offers.
Subscribers will have instant access to the Dark Report library, 1997 - the present, giving you the most convenient, accessible archive available in laboratory business intelligence today!
To read our FREE article previews, go to The Dark Report Insider.